1. Stocks
    2. /
  2. Neuren Pharmaceuticals Limited (ASX: NEU)
    3. /

Neuren Pharmaceuticals Limited (ASX: NEU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Neuren Pharmaceuticals Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Neuren Pharmaceuticals Limited (ASX: NEU)
    Latest News

    A man sees some good news on his phone and gives a little cheer.
    Broker Notes

    These ASX shares could rise 20% to 60%

    | James Mickleboro

    Analysts see major upside potential for these stocks.

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Fallers

    Why Light & Wonder, Neuren, Nick Scali, and QBE shares are falling today

    | James Mickleboro

    These shares are having a tough session on Friday. But why?

    Read more »

    Health professional working on his laptop.
    Healthcare Shares

    Why are Neuren Pharmaceuticals shares crashing 9%?

    | James Mickleboro

    The market may be storming higher but this biotech stock isn’t. But why?

    Read more »

    Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
    Best Shares

    Which ASX 200 market sector has been the best performer over 10 years?

    | Bronwyn Allen

    This might surprise you...

    Read more »

    A person sitting at a desk smiling and looking at a computer.
    Broker Notes

    3 ASX shares poised to rise 50% by 2025

    | Zach Bristow

    In a volatile market, these names could outshine next year.

    Read more »

    A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
    Healthcare Shares

    This ASX 200 healthcare share is frozen amid 'slower than expected' growth

    | Zach Bristow

    Investors have a bit to digest after today's updates.

    Read more »

    A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
    Healthcare Shares

    This ASX stock could rise 60%+

    | James Mickleboro

    Bell Potter sees major upside for this buy-rated stock. But why?

    Read more »

    A man with a wide, eager smile on his face holds up three fingers.
    Broker Notes

    3 of the best ASX 200 shares to buy in August

    | James Mickleboro

    Looking for big returns? Brokers think these shares could provide them.

    Read more »

    Hands reaching high for a trophy with a sunset in the background.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was another day and another record high for ASX shares this Wednesday.

    Read more »

    A woman's hand draws a stylised 'Top Ten' on a projected surface.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was back to earth for ASX investors this Tuesday.

    Read more »

    happy investor, share price rise, increase, up
    Growth Shares

    These top ASX 200 growth shares could rise 20% to 45%

    | James Mickleboro

    These growth stocks have been named as buys by brokers and tipped to rise strongly.

    Read more »

    Three smiling corporate people examine a model of a new building complex.
    Share Market News

    Shares vs. property: Which stocks and suburbs delivered the best growth in FY24?

    | Bronwyn Allen

    We reveal the top 10 stocks and best city vs. regional markets in FY24.

    Read more »

    Frequently Asked Questions

    No, Neuren Pharmaceuticals does not pay dividends at this time. 

    Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.

    NEU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Neuren Pharmaceuticals Limited

    Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

    In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

    Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

    Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

    Profile

    since

    Note